Gc012f asco
WebJun 2, 2024 · 8005 Background: GC012F is a B cell maturation antigen (BCMA)/CD19 dual-targeting CAR-T developed on the novel FasT CAR-T platform with overnight … WebMay 26, 2024 · GC012F is currently being evaluated in IITs in China including in MM and B-NHL. "We are thrilled to present updated data from our ongoing study of GC012F for the treatment of patients with RRMM at the oral abstract session at ASCO," said Dr. Martina A. Sersch, Chief Medical Officer of Gracell. "GC012F is the first dual-targeting CAR-T with ...
Gc012f asco
Did you know?
WebAug 17, 2024 · GC012F is a FasTCAR-enabled dual-targeting BCMA/CD19 autologous chimeric antigen receptor (CAR)-T cell therapy that is currently being studied in an ongoing Phase 1 investigator-initiated trial (IIT) in China for the treatment of MM patients who are relapsed from or refractory to (r/r) prior therapies. Interim data presented at ASCO & EHA. WebBackground: GC012F is a B cell maturation antigen (BCMA)/CD19 dual-targeting CAR-T developed on the novel FasT CAR-T platform with overnight manufacturing and …
WebApr 28, 2024 · Additional information about the presentation and the ASCO Annual Meeting is available on the ASCO website. About GC012F. GC012F is a FasTCAR-enabled dual-targeting CAR-T product candidate that is currently being evaluated in IIT studies in China for the treatment of multiple myeloma (MM) and B-cell non-Hodgkin's lymphoma (B … WebJun 5, 2024 · Investigators at the 2024 American Society of Clinical Oncology (ASCO) annual meetingare sharing outcomes for 9 additional patients in updated results from a first-in-human study (NCT04236011; NCT04182581) of GC012F, a B cell maturation antigen (BCMA)/CD19 dual-targeting CAR-T for patients with relapsed/refractory multiple …
WebMay 24, 2024 · Hello, I Really need some help. Posted about my SAB listing a few weeks ago about not showing up in search only when you entered the exact name. I pretty … WebApr 14, 2024 · The complete title of the abstract will be released on meetings.asco.org on April 27, 2024 and the text of abstract will be posted on May 26, 2024 at 5:00 PM EDT. …
WebMay 28, 2024 · 8014 Background: The dual CAR-T GC012F developed on the novel FasT CAR-T platform targeting B cell maturation antigen (BCMA), and CD19 was designed to …
WebBackground: GC012F is a B cell maturation antigen (BCMA)/CD19 dual-targeting CAR-T developed on the novel FasT CAR-T platform with overnight manufacturing and designed to improve depth of re- sponse and efficacy.Data was … csw foundationWebJun 11, 2024 · June 11, 2024. The (virtual) 2024 American Society of Clinical Oncology (ASCO) took place on June 4-8. This year brought us several updates in multiple myeloma relating to: Minimal residual disease (MRD) Chimeric antigen receptor (CAR) T-cell therapies. Treatment for high-risk disease. Second primary malignancies in African … earning a teaching degree onlineWebJun 5, 2024 · This project, GC012F, has generated an 83% ORR among 28 patients, and all 27 patients evaluable for MRD status were negative; 87.5% of eight patients evaluable at 12 months remained MRD-negative. The … csw footballWebApr 14, 2024 · Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2024 ASCO Annual Meeting Read full article April 14, 2024, 5:30 AM · 4 min ... csw for social workersWebJun 6, 2024 · Presented at: 2024 ASCO Annual Meeting, June 3-7, 2024. Abstract # 8004. 5. Du J, Jiang H, Dong B, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Presented at: 2024 ASCO Annual Meeting, June 3-7, 2024. … csw film systemsWebMay 19, 2024 · 2024 ASCO Annual Meeting Abstract 8014: Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 targeted FasTCAR-T GC012F … csw formatocswf qualifications